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REPORT
Linkage of Monogenic Infantile Hypertrophic Pyloric Stenosis to
Chromosome 16p12-p13 and Evidence for Genetic Heterogeneity
Francesca Capon, Ashley Reece, Rathi Ravindrarajah, and Eddie Chung
Infantile hypertrophic pyloric stenosis (IHPS) is the most common form of bowel obstruction in infancy. The disease
affects males four times more often than females and is considered a paradigm for the sex-modiﬁedmodel ofmultifactorial
inheritance. However, pedigrees consistent with autosomal dominant inheritance have also been documented. We an-
alyzed a 3-generation family with IHPS including 10 affected individuals (5 males and 5 females) and mapped the
underlying disease locus to chromosome 16p12-p13 (LOD score 3.23) by using a single-nucleotide polymorphism–based
genomewide scan. The analysis of 10 additional multiplex pedigrees yielded negative or nonsigniﬁcant LOD scores,
indicating the presence of locus heterogeneity. Sequence analysis of candidate genes from the chromosome 16 disease
interval excluded the presence of pathogenic mutations in the GRIN2A and MYH11 genes.
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Infantile hypertrophic pyloric stenosis (IHPS [MIM
#179010]) is an inherited form of bowel obstruction af-
fecting up to 8 in 1,000 newborns. The disease is char-
acterized by a marked hypertrophy of the pylorus smooth
muscle, which leads to a blockage of the gastric outlet and
provokes increasingly severe episodes of projectile vom-
iting. Effective IHPS treatment requires surgical interven-
tion to relieve the bowel blockage.1
IHPS has been associated with a number of inherited
syndromes (e.g., Smith-Lemli-Opitz andCornelia de Lange
syndromes) and with a variety of chromosomal abnor-
malities.2–5 Nonsyndromic IHPS shows familial aggrega-
tion, and the classic studies of Carter and Evans6 deﬁned
the disease as a paradigm for the multifactorial, sex-mod-
iﬁed threshold model of inheritance.
The pylorus hypertrophy underlying IHPS is thought to
result from a failure to relax the sphincter smoothmuscle.
It has been proposed that disease susceptibility may be
associated with a diminished production of nitric oxide,
the main mediator of smooth-muscle relaxation in the
gastrointestinal tract.7 In particular,NOS1 (MIM *163731),
the gene encoding neuronal nitric oxide synthase, has
been implicated in the disease pathogenesis by expression
studies, animal models, and genetic analyses of small IHPS
data sets.8–10
Despite well-documented evidence of multifactorial in-
heritance of IHPS, multigeneration families consistent
with autosomal dominant transmission of the disease
have also been described.11,12 We report here a linkage
analysis of several extended pedigrees and the identiﬁ-
cation of the ﬁrst locus for monogenic IHPS.
As part of our ongoing research on common and com-
plex forms of IHPS, we ascertained a data set of nuclear
and multiplex pedigrees through collaborations with sev-
eral centers for pediatric surgery (Great Ormond Street
Hospital, The Royal LondonHospital, and St George’sHos-
pital, London; and Karolinska Institute, Stockholm).Three
northern European families (IHPS021, IHPS036, and
IHPS078; ﬁg. 1)—including more than six affected indi-
viduals and presentingwith a disease-transmissionpattern
consistent with autosomal dominant inheritance—were
selected for this study. In all patients, IHPS was diagnosed
according to standard clinical criteria and was conﬁrmed
during pyloromyotomy. All individuals who participated
in the study granted their informed consent. Ethical ap-
proval was obtained from the Ethics Committee of Uni-
versity College London Hospital and from the relevant
committees of all hospitals involved in the family-ascer-
tainment effort.
We ﬁrst excluded linkage to NOS1 in the three extended
pedigrees by genotyping a set of intragenic microsatellite
markers (NOS1a, NOS1b, and NOS1e29; primer sequences
and cycling conditions are available on request). Para-
metric linkage analysis was performed using Merlin 1.0,13
under the assumption of autosomal dominant inheritance
with reduced penetrance. Negative LOD scores were ob-
served in all three families for 60% and 95% penetrance
values (table 1).
Having excluded linkage to NOS1, we undertook a ge-
nomewide linkage scan of family IHPS036, which in-
cluded the largest number of affected individuals. A total
of 16 individuals (the 9 living affected individuals and 7
unaffected relatives; ﬁg. 1) were genotyped using Illumina
Linkage Panel IV, which consists of 5,850 SNP markers
spaced at an average distance of 0.64 cM. Fourmicrograms
of genomic DNA from each individual was analyzed on a
BeadArray platform (Illumina), by use of GoldenGate as-
say (Illumina) reagents. Both parametric and nonpara-
metric linkage analyses were performed usingMerlin 1.0.13
On the basis of the IHPS transmission pattern observed
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Figure 1. The three multigeneration IHPS pedigrees. Biological samples were obtained from all living individuals, except those marked
with an asterisk (*). No samples were obtained from any of the deceased family members. Question marks (?) indicate individuals
whose disease status could not be determined.
Table 1. Linkage Analysis of the NOS1 Genomic Region
in Three Multigeneration Pedigrees, with 60% or 95%
Penetrance
Marker
(Position)
Multipoint LOD Score for Pedigree
IHPS021 IHPS036 IHPS078
60% 95% 60% 95% 60% 95%
NOS1a (5′ UTR) 2.08 1.93 4.6 5.9 5.0 4.5
NOS1b (intron 12) 2.08 1.93 4.5 5.8 5.7 5.2
NOS1e29 (3′ UTR) 2.08 1.93 4.0 4.8 5.0 4.5
Table 2. Summary of Results
of Genomewide Scan
Chromosome
LOD Score
Minimum Maximum
1 12.2 1.5
2 12.6 3.4
3 13.7 3.1
4 12.5 3.4
5 9.9 1.9
6 13.6 4.3
7 11.2 1.9
8 12.3 .8
9 9.9 2.8
10 11.1 1.9
11 13.2 4.8
12 12.0 3.5
13 13.9 1.0
14 10.9 3.0
15 11.2 3.1
16 11.3 3.2
17 13.8 5.5
18 12.0 1.4
19 11.7 2.1
20 10.6 .6
21 9.9 2.7
22 11.8 4.0
NOTE.—Multipoint LOD score 13 is
indicated by bold italics.
in family IHPS036, the parametric analysis of the genome
scan was implemented assuming autosomal dominant in-
heritance with 95% penetrance. The disease-allele fre-
quency and phenocopy rate were set at 0.001 and 0.0001,
respectively.
Multipoint LOD scores 13 were observed at a single ge-
nomic region (in bold italics in table 2), on chromosome
16p12-p13 (maximum LOD 3.23; ﬁg. 2A). A more detailed
analysis of this locus was undertaken, and LOD scores3
were observed across penetrance values ranging from 82%
(maximum LOD 3.01) to 100% (maximum LOD 3.31).
NPL analysis also conﬁrmed linkage to this interval (NPL
; ). Segregation analysis identiﬁed aZ p 9.5 P ! .00001mean
risk haplotype that was shared by all affected individuals
(ﬁg. 2B) and was not found in any of the unaffected sub-
jects. Critical recombination events that occurred in two
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Figure 2. Mapping of the IHPS disease locus to chromosome 16p.
A, Output of chromosome 16 multipoint LOD score analysis. B,
Deﬁnition of the disease interval by means of haplotype analysis.
The middle row (Founder) shows the SNP haplotype segregating
in the affected individuals from family IHPS036. The top and bot-
tom rows show the recombining haplotypes observed in subjects
36.206 and 36.301. Arrows indicate the sites of recombination,
and the genomic segment shared by all affected individuals is
underlined.
Table 3. Characteristics of the 10 Additional IHPS Pedigrees Used in Linkage Analysis
Characteristic
No. of Subjects in Pedigree
Total
No. of
SubjectsIHPS005 IHPS007 IHPS009 IHPS020 IHPS021 IHPS027 IHPS035 IHPS057 IHPS078 IHPS146
Affected (male:female ratio) 4 (1:1) 5 (4:1) 5 (5:0) 4 (3:1) 6 (2.5:1) 4 (1:4) 4 (1:3) 4 (1:1) 7 (1.6:1) 4 (4:0) 47 (1.8:1)
Unaffected 3 3 10 7 7 4 3 8 10 4 59
patients allowed us to deﬁne a 23-cM disease interval de-
limited by SNPs rs1035564 and rs1457907 (ﬁg. 2B).
Three microsatellite markers spanning the linkage in-
terval (D16S3052, D16S3075, and D16S405; primer se-
quences and cycling conditions are available on request)
were typed in the two remaining extended families
(IHPS021 and IHPS078). We also analyzed an additional
eight northern European multiplex pedigrees, which we
selected from a data set previously ascertained by Chung
et al.,8 on the basis of their negative LOD scores at the
NOS1 locus. The chromosome 16p microsatellite markers
yielded negative LOD scores in all examined families (ta-
bles 3 and 4), with the exception of a single pedigree (with
four affected individuals), which yielded positive but non-
signiﬁcant LOD scores (family IHPS005). Altogether, these
results indicated that the chromosome 16p linkage is spe-
ciﬁc to family IHPS036 and hindered a further reﬁnement
of the disease locus.
The IHPS interval identiﬁed by the genomewide scan
spans 11 Mb. The high marker density of the Illumina
Linkage Panel IV provided us with well-deﬁned bound-
aries for the disease interval, eliminating the need for fur-
ther ﬁne mapping. The distal end of the minimal IHPS
region is delimited by a recombination between rs1035564
and rs933478; these two markers are only 173 kb apart,
and no transcript has been mapped between them. Like-
wise, the recombination deﬁning the proximal bound-
ary of the IHPS locus occurred between two markers
(rs1457907 and rs936347) that are 75 kb apart and en-
compass no genes.
The 11-Mb disease locus includes a total of 65 genes.
We investigated the function and expression patterns of
all transcripts by mining the Ensembl, UniGene, and
GeneCards databases. We prioritized for mutational anal-
ysis the MYH11 (MIM *160745) and GRIN2A (MIM
*138253) genes, since they encode proteins with impor-
tant roles in smooth-muscle relaxation. MYH11 encodes
the heavy chain of myosin XI, the molecular motor that
powers smooth-muscle contraction.14 Four myosin iso-
forms are generated by alternative splicing of MYH11 and
are differentially expressed in various smooth-muscle cell
types.15 GRIN2A encodes the 2A subunit of ionotropic glu-
tamate receptors of the N-methyl-D-aspartate subtype.
These are ligand-gated ionic channels that mediate the
inﬂux of calcium into neurons, a crucial signal in the reg-
ulation of smooth-muscle relaxation.16
We examined all coding and UTR exons, as well as
exon-intron junctions, in both candidate genes. Puriﬁed
PCR products (primer sequences and cycling conditions
are available on request) were sequenced using an ABI
3100 Genetic Analyzer (Applied Biosystems). Nucleotide
changes were identiﬁed by visual inspection of chromat-
ograms. Several known SNPs were identiﬁed in both genes,
but no pathogenic mutation was observed.
With this study, we mapped the ﬁrst locus for mono-
genic IHPS through a SNP-based genome scan of a mul-
tigeneration pedigree. The sex-segregation male:female
ratio in family IHPS036 is 1:1. In our experience, the IHPS
male sex bias tends to be less pronounced in familial cases
(1.8:1 in our data set; table 3), which suggests that the
effect of the underlying mutations is unlikely to be mod-
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Table 4. Linkage Analysis of Chromosome 16p Microsatellite Markers in 10 Additional IHPS Pedigrees, with 60% or 95%
Penetrance
Marker
Multipoint LOD Score for Pedigree
IHPS005 IHPS007 IHPS009 IHPS020 IHPS021 IHPS027 IHPS035 IHPS057 IHPS078 IHPS146
60% 95% 60% 95% 60% 95% 60% 95% 60% 95% 60% 95% 60% 95% 60% 95% 60% 95% 60% 95%
D16S3052 1.9 .6 4.5 5.1 .4 .6 1.2 .02 5.9 6.5 3.1 4.3 2.2 1.4 5.1 3.8 8.1 5.7 .1 .2
D16S3075 .2 .2 6.4 7.0 .4 .6 .6 .02 5.5 3.4 2.9 3.4 .3 1.0 1.3 1.2 9.8 9.1 .2 .3
D16S405 .7 .6 6.4 7.0 .2 .4 1.3 .02 4.7 .6 2.6 3.0 .4 .3 1.8 1.1 7.1 3.2 2.4 1.6
iﬁed by sex-speciﬁc factors (e.g., hormone levels). Con-
versely, we did not observe any differences in the clinical
phenotype of family IHPS036 compared with the phe-
notypes of other familial or sporadic cases. The analysis
of an additional 10 families yielded negative or nonsig-
niﬁcant LOD scores, indicating that the chromosome 16
locus is speciﬁc to the highly penetrant mutation segre-
gating in family IHPS036.
The observation of genetic heterogeneity in a Mende-
lian subtype of a complex disease is not uncommon, and
several genes are known to be mutated in the monogenic
forms of breast cancer,17 Alzheimer disease,18 and matur-
ity-onset diabetes of the young.19 In the case of IHPS,
the presence of genetic heterogeneity is consistent with
the complexity of the molecular pathways underlying
smooth-muscle relaxation.20 Given the high number of
proteins involved in these signaling cascades, it is reason-
able to hypothesize that IHPSmay be caused bymutations
occurring in different genes and segregating with various
degrees of penetrance.
We sequenced the twomost prominent candidate genes
from the chromosome 16p linkage interval but did not
observe any pathogenic mutation. The identiﬁcation of
heterozygous genotypes at a number of SNP loci also rules
out the possibility that the disease is caused by the dele-
tion of either MYH11 or GRIN2A. We cannot exclude the
occurrence of a mutation in the promoter regions of either
gene. However, the high penetrance of the defect segre-
gating in family IHPS036 argues against the hypothesis of
a subtle regulatory mutation. It is also worth mentioning
that a recent report of dominant MYH11 mutations in
families with thoracic aortic aneurism21 makes this gene
a less likely candidate for IHPS.
The linkage interval identiﬁed in family IHPS036 con-
tains at least 21 anonymous cDNAs (Ensembl v37 Feb
2006), which we are currently characterizing using a range
of bioinformatic tools. We also plan to integrate results
obtained in silico with those of laboratory-based expres-
sion analyses; as more information on the functions and
expression patterns of these transcripts becomes available,
additional IHPS candidate genes should emerge. Advances
in the ﬁeld of smooth-muscle physiology could also help
to identify additional chromosome 16p genes that may
be involved in the relaxation of the pylorus sphincter.
The identiﬁcation of a disease locus is an important step
toward a better understanding of IHPS molecular patho-
genesis. Although our ﬁndings indicate that chromosome
16p is unlikely to be a common IHPS locus, the analysis
of additional family data sets will be needed to establish
how frequently this locus segregates with the disease. The
eventual identiﬁcation of the disease gene will also allow
an assessment of the contribution of chromosome 16p
mutations to sporadic IHPS.
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Web Resources
The URLs for data presented herein are as follows:
Ensembl, http://www.ensembl.org/Homo_sapiens/index.html
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Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for IHPS, NOS1, MYH11, and GRIN2A)
UniGene, http://www.ncbi.nlm.nih.gov/UniGene/
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